Triple or dual antithrombotic therapy post‐percutaneous coronary intervention: Which one is better?

Wern Yew Ding; Tatjana Potpara; Rod Stables; Professor Gregory Lip

doi:10.1111/jce.14130

Related publications

Article2022

Comparison of early clinical outcomes between dual antiplatelet therapy and triple antithrombotic therapy in patients with atrial fibrillation undergoing percutaneous coronary intervention

Jiesuck Park, Jin‐Hyung Jung, Eue-Keun Choi, Seung‐Woo Lee, Soonil Kwon, So-Ryoung Lee, Jeehoon Kang, Kyungdo Han, Kyung Woo Park, Seil Oh, Professor Gregory Lip

Article2024

Ticagrelor or Clopidogrel Monotherapy vs Dual Antiplatelet Therapy After Percutaneous Coronary Intervention

Marco Valgimigli, Felice Gragnano, Mattia Branca, Anna Franzone, Bruno R. da Costa, Usman Baber, Takeshi Kimura, Yangsoo Jang, Joo‐Yong Hahn, Qiang Zhao, Stephan Windecker, C. Michael Gibson, Hirotoshi Watanabe, Byeong‐Keuk Kim, Young Bin Song, Yunpeng Zhu, Pascal Vranckx, Shamir R. Mehta, Giuseppe Andò, Sung‐Jin Hong, Hyeon‐Cheol Gwon, Patrick W. Serruys, George Dangas, Eugène McFadden, Dominick J. Angiolillo, Dik Heg, Paolo Calabrò, Peter Jüni, Roxana Mehran

JAMA Cardiology

Article2022

Triple antithrombotic therapy and dual therapy – What is the evidence base?

Hani Essa, Rajiv Sankaranarayanan, L. Walker

Article2020

Triple therapy in patients with atrial fibrillation and acute coronary syndrome or percutaneous coronary intervention/stenting

Monika Kozieł, Tatjana Potpara, Professor Gregory Lip

Article2020

Antithrombotic therapy in patients with atrial fibrillation and acute coronary syndrome and / or undergoing percutaneous coronary intervention

M Mihajlović, M Marinković, Monika Kozieł, Nebojša Mujović, Professor Gregory Lip, Tatjana Potpara